Glutamate Modulation Platform
Troriluzole is our lead glutamate modulation platform candidate. It balances the glutamate system via glutamate transporter modulation.
Troriluzole is a new chemical entity (NCE) prodrug of the glutamate modulating agent riluzole. Troriluzole is currently in Phase III studies to treat OCD and SCA, the latter of which includes two centers in China. Both of these potential indications offer important market opportunities.
OCD is a common disease with an approximate lifetime prevalence of 1-3% in China. Public awareness of OCD is increasing through conversations about the disorder on social media platforms.
SCA is a rare, disabling neurodegenerative disease affecting about 70,000 patients in China and no FDA or NMPA approved medications. BioShin anticipates launching troriluzole for this orphan indication in 2023.
Troriluzole also has therapeutic potential in other diseases driven by glutamate toxicity, such as Friedreich’s ataxia, sporadic ataxia, hoarding disorder, and trichotillomania, which is also known as a hair-pulling disorder.